|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG; CGG; L858R) were found from 63 of 575 lung cancer patients.
|
16890322 |
2006 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas.
|
16705038 |
2006 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations (CTG-->CGG; L858R) were found from 14 of 95 lung cancer patients.
|
16003726 |
2006 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
|
20574956 |
2010 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The loop-hybrid mobility shift assay (LH-MSA) was previously developed for the rapid detection of the EGFR mutation L858R for predicting clinical responses to gefitinib in lung cancer.
|
21741959 |
2011 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Approximately 50% of lung cancer patients with epidermal growth factor receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) reportedly carry a secondary EGFR T790M mutation.
|
22899358 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In preclinical studies, afatinib not only inhibited the growth of models with common activating EGFR mutations, but was also active in lung cancer models harboring wild-type EGFR or the EGFR L858R/T790M double mutant.
|
23664448 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M resistance mutation.
|
23937717 |
2013 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified a reference range for EGFR L858R and exon 19 deletions in specimens from KRAS-mutant lung cancer, allowing identification of candidate thresholds with high sensitivity and 100% specificity.
|
24429876 |
2014 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Next, we examined the role of RhoB in lung cancer progression in transgenic mice that express inducible EGFR(L858R) crossed with Rhob null mice.
|
25320360 |
2014 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ectopic expression of EGFR-L858R in lung cancer cells acted through activation of ERK signaling pathways to induce the expression of CXCR4.
|
26338423 |
2015 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The posterior fossa, the anatomic "watershed areas," and the gray-white matter junction were confirmed to be more commonly affected by lung cancer brain metastases, and brain metastases with epidermal growth factor receptor (EGFR) L858R mutation occurred more often in the caudate, cerebellum, and temporal lobe than those with exon 19 deletion of EGFR.
|
26519739 |
2016 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
|
26689995 |
2016 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
|
27619632 |
2016 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
To further access a physiological role of MALT1-dependent NF-κB activation in EGFR-driven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Malt1(-/-)), in which mutant EGFR-driven lung cancer was developed in the absence of MALT1 expression.
|
25982276 |
2016 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Chemotherapy Drug Response to the L858R-induced Conformational Change of EGFR Activation Loop in Lung Cancer.
|
27643705 |
2016 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has led to unprecedented clinical response in a subset of lung cancer patients carrying the sensitizing EGFR mutations (L858R or exon 19 deletion).
|
28774798 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.
|
30268468 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation).
|
29462253 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
|
29753165 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.
|
29748615 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation.
|
29290255 |
2018 |